RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
Stock Information for Lineage Cell Therapeutics, Inc.
Loading
Please wait while we load your information from QuoteMedia.